1. African Swine Fever Virus EP364R and C129R Target Cyclic GMP-AMP To Inhibit the cGAS-STING Signaling Pathway
- Author
-
Niranjan Dodantenna, Lakmal Ranathunga, W. A. Gayan Chathuranga, Asela Weerawardhana, Ji-Won Cha, Ashan Subasinghe, Nuwan Gamage, D. K. Haluwana, YongKwan Kim, WeonHwa Jheong, Haryoung Poo, and Jong-Soo Lee
- Subjects
Phosphoric Diester Hydrolases ,Swine ,Sus scrofa ,Immunology ,Membrane Proteins ,Viral Vaccines ,Vaccines, Attenuated ,African Swine Fever Virus ,Nucleotidyltransferases ,Microbiology ,Viral Proteins ,Virology ,Insect Science ,Animals ,Interferons ,Nucleotides, Cyclic ,African Swine Fever ,Adaptor Proteins, Signal Transducing ,Immune Evasion ,Signal Transduction - Abstract
African swine fever virus (ASFV) is a highly pathogenic swine DNA virus with high mortality that causes African swine fever (ASF) in domestic pigs and wild boars. For efficient viral infection, ASFV has developed complex strategies to evade key components of antiviral innate immune responses. However, the immune escape mechanism of ASFV remains unclear. Upon ASFV infection, cyclic GMP-AMP (2',3'-cGAMP) synthase (cGAS), a cytosolic DNA sensor, recognizes ASFV DNA and synthesizes the second messenger 2',3'-cGAMP, which triggers interferon (IFN) production to interfere with viral replication. In this study, we demonstrated a novel immune evasion mechanism of ASFV EP364R and C129R, which blocks cellular cyclic 2',3'-cGAMP-mediated antiviral responses. ASFV EP364R and C129R with nuclease homology inhibit IFN-mediated responses by specifically interacting with 2',3'-cGAMP and exerting their phosphodiesterase (PDE) activity to cleave 2',3'-cGAMP. Particularly notable is that ASFV EP364R had a region of homology with the stimulator of interferon genes (STING) protein containing a 2',3'-cGAMP-binding motif and point mutations in the Y76S and N78A amino acids of EP364R that impaired interaction with 2',3'-cGAMP and restored subsequent antiviral responses. These results highlight a critical role for ASFV EP364R and C129R in the inhibition of IFN responses and could be used to develop ASFV live attenuated vaccines.
- Published
- 2022
- Full Text
- View/download PDF